Kevzara® (Sarilumab) Approved by FDA As First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has approved Kevzara® for the treatment of polymyalgia rheumatica, an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.